Janux Therapeutics Inc (JANX) Stock Analysis

Janux Therapeutics Inc (JANX) is a publicly traded company in the HEALTHCARE sector. It trades at $13.78, carries a market capitalization of $889.76M. This page summarizes the public market data, fundamentals, and frequently asked questions for JANX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Janux Therapeutics Inc currently has a Bullish sentiment score of 0.41.

About Janux Therapeutics Inc

Janux Therapeutics, Inc. is an innovative biopharmaceutical company based in La Jolla, California, specializing in the development of advanced immunotherapies for cancer treatment through its proprietary Tumor Activated T Cell Engager (TRACTr) platform. The company aims to enhance patient outcomes by creating therapies that specifically target and eliminate tumor cells, addressing critical unmet needs in oncology. With a strong emphasis on T cell biology and tumor activation mechanisms, Janux...

GNG Research Analysis

GNG Research scores Janux Therapeutics Inc (JANX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for JANX.

Frequently Asked Questions

Does JANX pay dividends?

Janux Therapeutics Inc (JANX) does not currently pay a regular dividend.

What is JANX's market cap?

Janux Therapeutics Inc (JANX) has a market capitalization of $889.76M with a current stock price of $13.78.